schliessen

Filtern

 

Bibliotheken

Successful Management of a Rare Cause of Hemolytic Uremic Syndrome With Eculizumab in a Child

BACKGROUND:: Hemolytic uremic syndrome (HUS) is characterized by microangiopathic hemolytic anemia, acute renal failure, and thrombocytopenia. It very rarely coexists with acute lymphoblastic leukemia (ALL) emerging before, simultaneously, or after the diagnosis has been made, and management of the... Full description

Journal Title: Journal of Pediatric Hematology/Oncology 2018, Vol.40(5), pp.401-404
Main Author: Alparslan, P., Caner
Other Authors: Yavaşcan, P., Önder , Kasap Demir, P., Belde , Atmiş, P., Bahriye , Karabay Bayazit, P., Aysun , Leblebisatan, P., Göksel , Öncel, P., Elif , Alaygut, P., Demet , Mutlubaş, P., Fatma , Aksu, P., Nejat
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 1077-4114 ; DOI: 10.1097/MPH.0000000000001121
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: ovid10.1097/MPH.0000000000001121
title: Successful Management of a Rare Cause of Hemolytic Uremic Syndrome With Eculizumab in a Child
format: Article
creator:
  • Alparslan, P., Caner
  • Yavaşcan, P., Önder
  • Kasap Demir, P., Belde
  • Atmiş, P., Bahriye
  • Karabay Bayazit, P., Aysun
  • Leblebisatan, P., Göksel
  • Öncel, P., Elif
  • Alaygut, P., Demet
  • Mutlubaş, P., Fatma
  • Aksu, P., Nejat
subjects:
  • Hemolytic-Uremic Syndrome – Case Studies
  • Hemolytic-Uremic Syndrome – Development and Progression
  • Hemolytic-Uremic Syndrome – Care and Treatment
  • Pediatric Diseases – Case Studies
  • Pediatric Diseases – Development and Progression
  • Pediatric Diseases – Care and Treatment
ispartof: Journal of Pediatric Hematology/Oncology, 2018, Vol.40(5), pp.401-404
description: BACKGROUND:: Hemolytic uremic syndrome (HUS) is characterized by microangiopathic hemolytic anemia, acute renal failure, and thrombocytopenia. It very rarely coexists with acute lymphoblastic leukemia (ALL) emerging before, simultaneously, or after the diagnosis has been made, and management of the patient may be difficult. CASE:: We present the case of a 7-year-old boy who was diagnosed with HUS and initially managed by hemodialysis (HD). Thereafter, HUS progressed, and neurological findings developed. The patient was treated with eculizumab, agressive blood pressure control, and antiepileptic drugs. At the fifth month of follow-up, the patient was diagnosed with acute B-cell lymphoblastic leukemia with fever, bone pain, hepatosplenomegaly, and pancytopenia. After initiation of ALL treatment, he had no episodes of HUS, despite cessation of eculizumab. CONCLUSION:: In conclusion, eculizumab may be a treatment of choice to prevent further systemic damage in recurrent HUS episodes of patients with borderline changes in the bone marrow until ALL is constantly diagnosed.
language:
source:
identifier: ISSN: 1077-4114 ; DOI: 10.1097/MPH.0000000000001121
fulltext: fulltext
issn:
  • 1077-4114
  • 10774114
url: Link


@attributes
ID220344769
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1097/MPH.0000000000001121
sourceidovid
recordidTN_ovid10.1097/MPH.0000000000001121
sourceformatXML
sourcesystemOther
pqid2019043692
galeid544290489
display
typearticle
titleSuccessful Management of a Rare Cause of Hemolytic Uremic Syndrome With Eculizumab in a Child
creatorAlparslan, P., Caner ; Yavaşcan, P., Önder ; Kasap Demir, P., Belde ; Atmiş, P., Bahriye ; Karabay Bayazit, P., Aysun ; Leblebisatan, P., Göksel ; Öncel, P., Elif ; Alaygut, P., Demet ; Mutlubaş, P., Fatma ; Aksu, P., Nejat
ispartofJournal of Pediatric Hematology/Oncology, 2018, Vol.40(5), pp.401-404
identifierISSN: 1077-4114 ; DOI: 10.1097/MPH.0000000000001121
descriptionBACKGROUND:: Hemolytic uremic syndrome (HUS) is characterized by microangiopathic hemolytic anemia, acute renal failure, and thrombocytopenia. It very rarely coexists with acute lymphoblastic leukemia (ALL) emerging before, simultaneously, or after the diagnosis has been made, and management of the patient may be difficult. CASE:: We present the case of a 7-year-old boy who was diagnosed with HUS and initially managed by hemodialysis (HD). Thereafter, HUS progressed, and neurological findings developed. The patient was treated with eculizumab, agressive blood pressure control, and antiepileptic drugs. At the fifth month of follow-up, the patient was diagnosed with acute B-cell lymphoblastic leukemia with fever, bone pain, hepatosplenomegaly, and pancytopenia. After initiation of ALL treatment, he had no episodes of HUS, despite cessation of eculizumab. CONCLUSION:: In conclusion, eculizumab may be a treatment of choice to prevent further systemic damage in recurrent HUS episodes of patients with borderline changes in the bone marrow until ALL is constantly diagnosed.
source
subjectHemolytic-Uremic Syndrome – Case Studies ; Hemolytic-Uremic Syndrome – Development and Progression ; Hemolytic-Uremic Syndrome – Care and Treatment ; Pediatric Diseases – Case Studies ; Pediatric Diseases – Development and Progression ; Pediatric Diseases – Care and Treatment;
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutOvid.html$$EView_Wolters_Kluwer_Health,_Lippincott,_Williams_&_Wilkins_Copyright_Statement
search
creatorcontrib
0Alparslan, P, Caner
1Yavaşcan, P, Önder
2Kasap Demir, P, Belde
3Atmiş, P, Bahriye
4Karabay Bayazit, P, Aysun
5Leblebisatan, P, Göksel
6Öncel, P, Elif
7Alaygut, P, Demet
8Mutlubaş, P, Fatma
9Aksu, P, Nejat
titleSuccessful Management of a Rare Cause of Hemolytic Uremic Syndrome With Eculizumab in a Child
descriptionBACKGROUND:: Hemolytic uremic syndrome (HUS) is characterized by microangiopathic hemolytic anemia, acute renal failure, and thrombocytopenia. It very rarely coexists with acute lymphoblastic leukemia (ALL) emerging before, simultaneously, or after the diagnosis has been made, and management of the patient may be difficult. CASE:: We present the case of a 7-year-old boy who was diagnosed with HUS and initially managed by hemodialysis (HD). Thereafter, HUS progressed, and neurological findings developed. The patient was treated with eculizumab, agressive blood pressure control, and antiepileptic drugs. At the fifth month of follow-up, the patient was diagnosed with acute B-cell lymphoblastic leukemia with fever, bone pain, hepatosplenomegaly, and pancytopenia. After initiation of ALL treatment, he had no episodes of HUS, despite cessation of eculizumab. CONCLUSION:: In conclusion, eculizumab may be a treatment of choice to prevent further systemic damage in recurrent HUS episodes of patients with borderline changes in the bone marrow until ALL is constantly diagnosed.
general
010.1097/MPH.0000000000001121
1Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
2Lippincott Williams & Wilkins - Journals
sourceidovid
recordidovid10.1097/MPH.0000000000001121
issn
01077-4114
110774114
rsrctypearticle
creationdate2018
addtitleJournal of Pediatric Hematology/Oncology
searchscopeovid
scopeovid
lsr30VSR-Enriched:[eissn, subject, pqid, galeid]
sort
titleSuccessful Management of a Rare Cause of Hemolytic Uremic Syndrome With Eculizumab in a Child
authorAlparslan, P., Caner ; Yavaşcan, P., Önder ; Kasap Demir, P., Belde ; Atmiş, P., Bahriye ; Karabay Bayazit, P., Aysun ; Leblebisatan, P., Göksel ; Öncel, P., Elif ; Alaygut, P., Demet ; Mutlubaş, P., Fatma ; Aksu, P., Nejat
creationdate20180700
facets
frbrgroupid8838047428459487657
frbrtype5
newrecords20190220
creationdate2018
collectionLippincott Williams & Wilkins Journals (Wolters Kluwer Health)
prefilterarticles
rsrctypearticles
creatorcontrib
0Alparslan, P., Caner
1Yavaşcan, P., Önder
2Kasap Demir, P., Belde
3Atmiş, P., Bahriye
4Karabay Bayazit, P., Aysun
5Leblebisatan, P., Göksel
6Öncel, P., Elif
7Alaygut, P., Demet
8Mutlubaş, P., Fatma
9Aksu, P., Nejat
jtitleJournal of Pediatric Hematology/Oncology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Alparslan
1Yavaşcan
2Kasap Demir
3Atmiş
4Karabay Bayazit
5Leblebisatan
6Öncel
7Alaygut
8Mutlubaş
9Aksu
aufirst
0Caner
1Önder
2Belde
3Bahriye
4Aysun
5Göksel
6Elif
7Demet
8Fatma
9Nejat
auinitmP.
au
0Alparslan, P., Caner
1Yavaşcan, P., Önder
2Kasap Demir, P., Belde
3Atmiş, P., Bahriye
4Karabay Bayazit, P., Aysun
5Leblebisatan, P., Göksel
6Öncel, P., Elif
7Alaygut, P., Demet
8Mutlubaş, P., Fatma
9Aksu, P., Nejat
atitleSuccessful Management of a Rare Cause of Hemolytic Uremic Syndrome With Eculizumab in a Child
jtitleJournal of Pediatric Hematology/Oncology
risdate201807
volume40
issue5
spage401
epage404
pages401-404
issn1077-4114
formatjournal
genrearticle
ristypeJOUR
abstractBACKGROUND:: Hemolytic uremic syndrome (HUS) is characterized by microangiopathic hemolytic anemia, acute renal failure, and thrombocytopenia. It very rarely coexists with acute lymphoblastic leukemia (ALL) emerging before, simultaneously, or after the diagnosis has been made, and management of the patient may be difficult. CASE:: We present the case of a 7-year-old boy who was diagnosed with HUS and initially managed by hemodialysis (HD). Thereafter, HUS progressed, and neurological findings developed. The patient was treated with eculizumab, agressive blood pressure control, and antiepileptic drugs. At the fifth month of follow-up, the patient was diagnosed with acute B-cell lymphoblastic leukemia with fever, bone pain, hepatosplenomegaly, and pancytopenia. After initiation of ALL treatment, he had no episodes of HUS, despite cessation of eculizumab. CONCLUSION:: In conclusion, eculizumab may be a treatment of choice to prevent further systemic damage in recurrent HUS episodes of patients with borderline changes in the bone marrow until ALL is constantly diagnosed.
pubCopyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
doi10.1097/MPH.0000000000001121
eissn15363678
date2018-07